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Summary
Objective:	Loss-	of-	function	mutations	in	 IGSF1	result	 in	X-	linked	central	congenital	
hypothyroidism	(CeCH),	occurring	in	isolation	or	associated	with	additional	pituitary	
hormone	deficits.	Intrafamilial	penetrance	is	highly	variable	and	a	minority	of	hete-
rozygous	females	are	also	affected.	We	 identified	and	characterized	a	novel	 IGSF1 
mutation	and	investigated	its	associated	phenotypes	in	a	large	Irish	kindred.
Design, Patients and Measurements:	A	novel	hemizygous	IGSF1	mutation	was	identi-
fied	by	direct	sequencing	in	two	brothers	with	CeCH,	and	its	functional	consequences	
were	characterized	in	vitro.	Genotype-	phenotype	correlations	were	investigated	in	
the	wider	kindred.
Results:	 The	 mutant	 IGSF1	 protein	 (c.2318T	>	C,	 p.L773P)	 exhibited	 decreased	
plasma	membrane	expression	in	vitro	due	to	impaired	trafficking	from	the	endoplas-
mic	reticulum.	Ten	hemizygous	males	and	11	heterozygous	females	exhibited	charac-
teristic	endocrine	deficits.	Ireland	operates	a	TSH-	based	CH	screening	programme,	
which	does	not	detect	CeCH;	therefore,	genetic	ascertainment	preceded	biochemical	
diagnosis	of	moderate	CH	in	five	of	seven	boys	as	well	as	their	75-	year-	old	grandfa-
ther.	 Clinical	 features	 potentially	 attributable	 to	 hypothyroidism	 were	 variable;	
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
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1  | INTRODUC TION
Central	congenital	hypothyroidism	(CeCH)	is	a	rare	entity	affecting	up	
to	one	in	16	000	individuals,1	and	occurs	when	hypothalamic	and/or	
pituitary	pathology	results	in	inadequate	thyrotropin	(TSH)-	mediated	
stimulation	of	the	thyroid	gland.2	Subnormal	circulating	free	thyroxine	
(FT4)	concentrations	in	CeCH	are	associated	with	a	failure	of	compen-
satory	TSH	elevation,	therefore	CeCH	evades	detection	by	the	TSH-	
based	UK	and	Irish	neonatal	congenital	hypothyroidism	(CH)	screening	
programmes,	 and	delayed	diagnosis	may	 result	 in	 adverse	auxologi-
cal	or	neurodevelopmental	sequelae.3	Underlying	genetic	aetiologies	
for	CeCH	include	mutations	 in	pituitary	transcription	factors,	which	
usually	manifest	as	multiple	pituitary	hormone	deficits.	Additionally,	
recessively	inherited	TSHB and TRHR	mutations,	or	X-	linked	mutations	
in TBL1X or IGSF1	may	present	as	isolated	TSH	deficiency.2,4-6
Since	the	initial	description	of	IGSF1	mutations	in	eleven	European	
kindreds,	larger	studies	have	substantiated	the	complex	nature	of	the	
IGSF1	deficiency	 syndrome	as	well	 as	 confirming	 the	 relatively	 fre-
quent	occurrence	of	IGSF1	mutations	in	CeCH	cases.4,7 IGSF1	encodes	
a	transmembrane	immunoglobulin	superfamily	glycoprotein	that	un-
dergoes	co-	translational	proteolysis	such	that	only	its	seven	carboxy-	
terminal	 immunoglobulin	 loops	 are	 expressed	 extracellularly	 at	 the	
plasma	membrane.8	 The	majority	 of	 previously	 reported	 IGSF1 mu-
tations	adversely	affect	trafficking	and	membrane	localization	of	this	
carboxy-	terminal	domain9	 (Figure	1A).	 IGSF1	is	abundantly	detected	
at	mRNA	level	in	Rathke’s	pouch	and	adult	pituitary	gland4;	however,	
a	paucity	of	 reliable	 antibodies	has	hampered	expression	 studies	 in	
humans.	In	rodents,	differential	antibody	usage	has	yielded	divergent	
results;	IGSF1	protein	has	been	detected	in	all	cells	of	the	Pou1f1	(Pit1)	
lineage	in	murine	and	rat	pituitaries	using	one	custom	IGSF1-	CTD	an-
tibody4,10;	 however,	 a	 different,	 commercially	 available	 anti-	IGSF1	
antibody	(Genetex)	localized	IGSF1	to	thyrotropes	and	gonadotropes	
in	rats,	but	not	somatotropes	or	lactotropes.11	Despite	clinical	and	mu-
rine	data	supporting	a	role	for	IGSF1	in	regulation	of	TRH	action	in	the	
pituitary,	its	molecular	function	remains	undefined.4,12,13
Hormone	 deficiencies	 associated	 with	 IGSF1	 mutations	 may	
involve	all	 cells	of	 the	POU1F1	 lineage.	Hemizygous	males	 almost	
universally	exhibit	central	hypothyroidism	and	60%	have	basal	hy-
poprolactinaemia;	 a	 minority	 (~15%)	 exhibit	 transient	 childhood	
growth	hormone	(GH)	deficiency.9	Endocrine	evaluation	of	hetero-
zygous	females	usually	reveals	a	milder	phenotype	with	FT4	concen-
trations	 in	 the	 lower	 tertile	of	 the	normal	 range,	although	18%	do	
exhibit	overt	central	hypothyroidism	and	22%	have	subnormal	basal	
prolactin.7,9	Affected	boys	exhibit	delayed	pubertal	testosterone	rise	
and	growth	spurt,	associated	with	preserved	testicular	growth	and	
development	of	macroorchidism	from	late	adolescence	onwards.4,9 
Additional	features	include	raised	BMI,	and	mildly	elevated	or	high-	
normal	adult	IGF-	1	concentrations.7,9
Biochemical	and	physiological	severity	of	CeCH	are	variable	
in	 IGSF1	 deficiency	 (including	 in	 congenic	mouse	 strains),	 and	
some	 individuals	 tolerate	 lifelong	 thyroid	 hormone	 deficiency	
without	apparent	adverse	consequences,	whereas	others	pres-
ent	symptomatically	early	on.4,9,11	Here,	we	describe	a	large	Irish	
kindred	 in	 which	 two	male	 siblings	 with	 CeCH	were	 found	 to	
harbour	a	novel	missense	IGSF1	mutation.	In	vitro	evaluation	of	
the	mutant	 IGSF1	protein	demonstrated	reduced	plasma	mem-
brane	 expression.	 Family	 screening	 identified	 eight	 additional	
hemizygous	 males	 and	 11	 heterozygous	 females	 who	 subse-
quently	underwent	endocrine	evaluation.	Tissue	manifestations	
of	hypothyroidism	reflect	the	pleiotropic	effects	of	thyroid	hor-
mone	and	in	childhood	may	include	growth	retardation,	delayed	
bone	 age	 or	 neurodevelopmental	 milestones,	 and	 prolonged	
neonatal	 jaundice.	 Affected	 children	 and	 adults	 may	 also	 ex-
hibit	 bradycardia,	 hypothermia,	 overweight	 and	 dyslipidaemia	
and	may	describe	constipation	and	fatigue.14	Biochemical	sever-
ity	of	hypothyroidism	was	usually	moderate	 in	our	kindred	and	
some	 cases	 appeared	 to	 tolerate	 hypothyroidism	 remarkably	
well,	whereas	seven	individuals	exhibited	adverse	sequelae	po-
tentially	attributable	to	thyroid	hormone	deficiency.	Our	obser-
vations	 support	 the	 notion	 that	 although	 some	 individuals	 are	
apparently	 asymptomatic	 despite	 significant	 central	 hypothy-
roidism,	 family	 screening	 in	 this	 context	 remains	 crucial	 in	 en-
abling	prompt	diagnosis	in	cases	where	growth	and	development	
may	otherwise	be	impaired.
normal	free	T3	(FT3)	and	low/low	normal	reverse	T3	(rT3)	concentrations	suggested	
that	preferential	deiodination	of	FT4	to	FT3	may	help	maintain	tissue	euthyroidism	in	
some	individuals.	However,	neonatal	jaundice,	delayed	speech	or	growth,	and	obesity	
were	observed	in	seven	subjects	in	whom	diagnosis	was	delayed.
Conclusions:	As	observed	with	other	 IGSF1	mutations,	p.L773P	 results	 in	variably	
penetrant	 IGSF1	 deficiency	 syndrome.	 Our	 observations	 emphasize	 the	 need	 for	
multi-	generation	genetic	ascertainment	 in	affected	families,	especially	where	TSH-	
based	CH	screening	programmes	may	fail	to	detect	CeCH	at	birth.
K E Y W O R D S
central	hypothyroidism,	congenital	hypothyroidism,	growth,	hypopituitarism,	IGSF1,	pituitary,	
thyroid
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2  | MATERIAL S AND METHODS
The	study	was	approved	by	Cambridge	South	REC	(MREC	98/5/24)	
and	includes	additional	measurements	undertaken	as	part	of	routine	
clinical	follow-	up	with	consent	from	patients	and/or	next	of	kin.
2.1 | Sanger sequencing of IGSF1
Genomic	DNA	was	extracted	from	peripheral	blood	leukocytes	
using	standard	techniques.	In	the	probands,	all	20	IGSF1	exons	
and	 exon/intron	 boundaries	 were	 amplified	 by	 PCR	 using	
specific	 primers	 (available	 on	 request).	 Family	members	were	
genotyped	 for	 the	 identified	missense	mutation	 (see	 Results)	
by	 amplifying	 and	 sequencing	 exon	 13	 alone.	 PCR	 products	
were	 sequenced	 using	 the	 BigDye	 Terminator	 v3.1	 Cycle	
Sequencing	Kit	(Applied	Biosystems,	Foster	City,	CA)	and	3730	
DNA	Analyzer	 (Applied	 Biosystems).	 The	 IGSF1	 variant	 listed	
in	 this	 study	 is	 described	 using	 the	 systematic	 nomenclature	
approved	 by	 the	 Human	 Genome	 Variation	 Society	 (HGVS;	
www.hgvs.org/mutnomen).	Nucleotide	numbering	starts	from	
the	A	(+1)	of	the	translation	initiation	codon	(ATG)	of	the	NCBI	
reference	 sequence	 NM_001170961.1.	 Amino	 acid	 residues	
are	 numbered	 according	 to	 the	 NCBI	 reference	 sequence	
NP_001164432.
2.2 | Clinical measurements
All	 biochemical	 measurements	 were	 performed	 in	 CPA	 (Clinical	
Pathology	 Accreditation)	 and	 INAB	 (Irish	 National	 Accreditation	
Board)	 accredited	 laboratories,	 using	 local	 automated	 assays,	 and	
results	were	compared	 to	 local	 reference	 ranges	 (age	and	gender-	
specific	 where	 appropriate).	 Auxological	 measurements	 were	
performed	 by	 trained	 auxologists	 during	 clinical	 visits,	 and	 SDS	
scores	 were	 computed	 according	 to	 published	 reference	 data15-17 
using	 GrowthXP	 Endo,	 a	 children	 growth	 monitoring	 commercial	
programme.
Relevant	medical	history	was	acquired	by	review	of	patients’	
notes	 or	 direct	 questioning.	 Unless	 otherwise	 stated,	 refer-
ence	 ranges	 refer	 to	95%	confidence	 intervals,	 and	variance	 is	
reported	 as	 standard	 deviation	 score.	 Sleeping	 heart	 rate	was	
compared	 to	 a	 locally-	generated	 reference	 range	 for	 healthy	
males	and	depicts	minimum	and	maximum.	Basal	metabolic	rate	
was	 measured	 using	 ventilated	 hood	 indirect	 calorimetry	 as	
	described	in.18
2.3 | TRH tests
TSH,	FT4,	free	triiodothyronine	(FT3)	and	prolactin	were	measured	
in	serum	samples	taken	at	baseline	and	at	20,	60,	90,	120,	150	and	
F IGURE  1 A,	Schematic	diagram	depicting	the	domain	structure	of	IGSF1	and	previously	reported	mutations.	Mutations	that	either	
truncate	the	carboxy-	terminus	or	have	been	shown	in	vitro	to	exhibit	impaired	plasma	membrane	expression	are	shown	in	black.	Missense	
mutations	that	associate	with	characteristic	endocrinopathy,	but	do	not	exhibit	clear	glycosylation	or	trafficking	defects	in	vitro	are	shown	
in	grey.	The	p.L773P	mutation	is	shown	in	bold	with	a	dashed	line.	B,	In	vitro	data	confirming	glycosylation	and	trafficking	defects	of	the	
p.L773P	mutant	protein.	HEK293	cells	were	transfected	with	empty	expression	vector	(pcDNA3,	left	lane),	or	expression	vectors	for	wild-	
type	(middle	lane)	or	p.L773P	(right	lane)	mutant	forms	of	HA-	tagged	IGSF1.	Cell	surface	proteins	were	biotinylated	prior	to	collection	of	
protein	lysates.	Proteins	were	either	examined	directly	by	immunoblot	(IB)	for	expression	of	IGSF1	(HA	antibody,	third	panel	from	the	top)	
or	for	β-	actin,	used	as	a	loading	control	(bottom	panel),	or	following	immunoprecipitation	(IP)	with	the	HA	antibody.	IP	proteins	were	then	
examined	by	IB	using	HA	to	confirm	precipitation	of	the	IGSF1	protein	(second	panel	from	the	top)	or	with	streptavidin	conjugated	to	HRP	to	
detect	IGSF1	at	the	plasma	membrane	(top	panel).	Molecular	weight	markers	(in	kDa)	are	labelled	at	the	left
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180	minutes	following	administration	of	200	micrograms	of	Protirelin	
(Thyrotrophin-	releasing	 hormone,	 TRH,	 Alliance	 Pharmaceuticals	
Ltd,	 Chippenham,	 UK).	 Hormone	 responses	 were	 compared	 with	
control	 subjects	 aged	 18-	67	years	 (mean	 33.8	±	13.7)	 from	Milan,	
Italy,	including	12	healthy	individuals	and	9	cases	with	nonfunction-
ing	microlesions	of	the	pituitary	(<5	mm	in	diameter)	without	pitui-
tary	hormone	deficits.
2.4 | Testicular volume assessment
Calculation	 of	 ultrasonographic	 testicular	 volume	 was	 com-
puted	 as	 previously	 described	 and	 compared	 with	 published	
reference	 data.19	 Testicular	 volumes	 in	 children	 were	 assessed	
clinically	by	a	trained	paediatric	endocrinologist	using	the	Prader	
Orchidometer.
2.5 | In vitro analysis of the mutant IGSF1 protein
The	 L773P	 mutation	 was	 introduced	 into	 the	 human	 
myc-	IGSF1-	HA	 expression	 vector	 described	 in8	 using	 the	
QuikChange	 mutagenesis	 protocol	 and	 the	 following	 primer	 set:	
(Forward:	 GCCCAGTGAGCCGCCGGAGCTTGTCATAA,	 Reverse:	
TTATGACAAGCTCCGGCGGCTCACTGGGC).	Mutant	and	wild-	type	
IGSF1	were	expressed	in	human	embryonic	kidney	(HEK)	293	cells.	
Transfections,	 cell	 surface	 biotinylation,	 immunoprecipitations,	
SDS-	PAGE	and	immunoblotting	were	performed	as	described	in.4
3  | RESULTS
3.1 | Patient histories
The	male	 Proband,	 3a	 (Figure	2),	 was	 born	 at	 term	 to	 nonconsan-
guineous	Irish	parents	(birth	weight	4.7	kg,	SDS	+2.49)	(Figures	2-5;	
Tables	1	and	2;	Tables	S1-	S3).	He	exhibited	mild	 transient	neonatal	
hypoglycaemia	 and	 jaundice,	 requiring	 24-	hour	 phototherapy.	 TSH	
screening	 results	were	normal;	however,	at	age	22	months,	he	was	
noted	to	be	obese	(weight	18.9	kg,	SDS	+4.09,	BMI	23.9	kg/m2,	SDS	
+4.0)	with	an	intermittently	subnormal	FT4	[9.1-	10.5	pmol/L	(RR	10-	
25)],	normal	TSH	[2.06-	3.5	mU/L	(RR	0.4-	4.0)]	and	undetectable	pro-
lactin	 [<10	mU/L	 (RR	90-	320	U/L)].	A	synacthen	test	demonstrated	
a	 normal	 cortisol	 response	 (basal	 cortisol	 204	mmol/L,	 30	minutes	
773	mmol/L,	60	minutes	802	mmol/L.	As	FT4	remained	low	normal,	
he	was	not	commenced	on	levothyroxine.	His	BMI	decreased	steadily	
with	dietary	intervention	and	development	was	normal.	However,	be-
tween	age	6.9	and	7.4	years,	the	previously	normal	annualized	height	
velocity	 declined	 to	 1.91	cm/y	 (height	 velocity	 SDS	 decrease	 from	
+0.1	to	−4.56)	and	growth	declined	from	height	SDS	+0.59	to	+0.21	
prompting	 re-	evaluation,	 which	 confirmed	 central	 hypothyroidism	
with	a	subnormal	FT4	[10.5	pmol/L	(RR	12-	22)],	FT3	at	the	lower	limit	
of	normal	[3.4	pmol/L	(RR	3.1-	6.8)]	and	inappropriately	normal	TSH	
[2.68	mU/L	(RR	0.3-	4.2)].	IGF-	1	[13.3	mmol/L	(RR	7-	40)]	and	IGFBP-	3	
[3.93	mg/L	 (RR	 1.1-	4.3)]	 were	 normal,	 and	 pituitary	 MR	 imaging	
was	unremarkable.	Height	SDS	remained	stable	and	height	velocity	
F IGURE  2 Pedigree	of	the	kindred	harbouring	the	p.L773P	mutation.	Hemizygous	males	are	shown	with	black	boxes;	heterozygous	
females	are	shown	with	a	central	black	dot.	Confirmed	or	obligate	wild-	type	cases	are	shown	in	white;	cases	who	have	not	been	tested,	
and	whose	genotype	is	unknown	are	in	grey.	Cases	are	annotated	with	ID,	age,	and	hormone	deficiencies,	including	central	hypothyroidism	
(CeCH),	hypoprolactinaemia	(PRL),	GH	deficiency	(GHD)	and	increased	IGF-	1	concentrations
     |  817ROCHE Et al.
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improved	steadily	with	levothyroxine	replacement	(SDS	−4.56	aged	
7.4	years	to	+1.12	aged	8.5	years,	see	growth	chart,	Figure	3).
His	 brother,	 3c,	 was	 born	 at	 42	weeks’	 gestation	 with	 a	 birth	
weight	 of	 4.48	kg	 (SDS	 +2.06).	 Neonatal	 jaundice	 was	 treated	
with	 phototherapy	 at	 postnatal	 days	 1	 and	 14	 but	 persisted	 for	
6	months	 with	 elevated	 transaminases.	 He	 had	 mild	 pulmonary	
branch	stenosis,	speech	delay	and	glue	ear.	At	age	2.3	years,	he	was	
noted	to	have	a	subnormal	FT4	[9.1	pmol/L	(RR	12-	22)]	with	a	nor-
mal	FT3	 [5.0	pmol/L	 (RR	3.1-	6.8)]	 and	 inappropriately	normal	TSH	
[2.73	mU/L	(RR	0.3-	4.2)].	Prolactin	was	low	at	79	mU/L	(RR	90-	320).	
He	also	exhibited	increased	weight	(17	kg,	SDS	+2.42,	BMI	20.6	kg/
m2,	 SDS	+2.92),	but	grew	along	 the	75th	percentile	with	a	normal	
height	velocity.	Levothyroxine	therapy	was	commenced,	and	he	has	
progressed	well	 at	 school;	 his	 speech	 is	now	also	normal.	The	oc-
currence	 of	 familial	 CeCH	with	 hypoprolactinaemia	 in	 one	 sibling	
prompted	screening	of	IGSF1,	which	identified	a	shared,	novel	mis-
sense	mutation,	c.2318T	>	C,	p.L773P	(Figures	1A,B	and	2).
3.2 | Pathogenicity of mutation
The	missense	variant	identified	was	absent	from	published	databases	
[dbSNP,	Exome	Aggregation	Consortium	(ExAC),	Cambridge,	MA	(URL:	
http://exac.broadinstitute.org),	 May	 2018]	 and	 altered	 a	 highly	 con-
served	amino	acid.	To	determine	the	potential	functional	impact	of	the	
p.L773P	variant,	we	expressed	the	wild-	type	and	mutant	forms	of	the	
protein	in	heterologous	HEK293	cells.	Wild-	type	IGSF1	migrates	as	a	
doublet	on	SDS-	PAGE	with	 the	higher	molecular	weight	band	 repre-
senting	 the	 mature,	 plasma	 membrane	 glycoform	 (Figure	1B,	 centre	
lane	in	the	middle	two	panels).	The	lower	molecular	weight	band	cor-
responds	to	the	immature,	endoplasmic	reticulum	(ER)-	retained	glyco-
form.	The	p.L773P	mutant	similarly	migrated	as	a	doublet,	but	with	a	
notable	reduction	in	the	abundance	of	the	mature	glycoform	(Figure	1B,	
right	most	 lane).	 Indeed,	 far	 less	 IGSF1-	 L773P	was	 observed	 at	 the	
plasma	membrane	 than	wild-	type	 IGSF1,	 as	 assessed	by	 cell	 surface	
biotinylation	(Figure	1B,	top	panel).	These	data	indicate	that	the	traffick-
ing	of	IGSF1-	L773P	out	of	the	ER	to	the	plasma	membrane	is	impaired.
3.3 | Additional genetic ascertainment and 
endocrine evaluation
Family	 screening	 identified	 an	 additional	 eight	 hemizygous	 males	
(five	 children	 and	 three	 adults)	 and	 eleven	 heterozygous	 females.	
Baseline	endocrinology	and	auxology	was	assessed,	and	dynamic	en-
docrine	testing	was	performed	in	a	subset	of	individuals	(Figures	2-5;	
Tables	1	and	2;	Supporting	Information	Tables	S1-	S3).
3.4 | Thyroid function
All	 evaluable	 male	 cases	 exhibited	 central	 hypothyroidism	 (FT4	
ranging	from	6.9	to	10.2	pmol/L,	mean	Z-	score	−3.3	±	0.4)	although	
biochemical	 penetrance	was	 variable.	 In	 all	 cases,	 FT3	 concentra-
tions	 were	 maintained	 within	 the	 reference	 range	 (mean	 Z-	score	
−0.8	±	0.8)	despite	a	subnormal	FT4,	and	 in	 three	evaluable	cases,	
this	was	achieved	at	the	expense	of	low/low	normal	reverse	T3	con-
centrations	 (Figures	2	 and	 4).	 Assessment	 of	 physiological	 thyroid	
status	 is	challenging	due	to	a	paucity	of	sensitive	and	specific	bio-
markers;	 however,	we	 screened	 our	 cases	 for	 features	 potentially	
attributable	 to	 tissue	 hypothyroidism	 including	 high	 birth	 weight,	
neonatal	 complications	 of	 hypothyroxinaemia,	 obesity,	 develop-
mental	delay,	growth	 impairment	and	symptoms	such	as	constipa-
tion	and	fatigue	(Table	1).	Three	of	seven	cases	for	whom	data	was	
available	 (3a,	3c,	3g)	 exhibited	birth	weight	SDS	 scores	of	 greater	
than	+2.0	and	case	1a	was	 reportedly	a	 “large	baby”	with	an	esti-
mated	birth	weight	of	around	4.5	kg;	cases	3d	and	3e	exhibited	low	
birth	 weight	 SDS	 which	 may	 have	 been	 attributable	 to	 maternal	
renal	disease.	One	child	and	two	adolescents	(cases	3a,	3h,	and	3i)	
with	 mild-	moderate	 central	 hypothyroidism,	 exhibited	 growth	 re-
tardation	or	a	decline	in	growth	velocity;	as	previously	detailed,	3a	
TABLE  2 Baseline	endocrinology	(Heterozygotes)
Case ID Age (y) TSH (0.3- 5.5 mU/L) fT4 (12- 22 pmol/L) fT3 (3.5- 6.5 pmol/L) PRL (Z score) IGF- 1 (Z score)
1d 66 2.17 13.2a 4.5 −0.9 2.2
2a 44.8 1.81 13.4 NA −1.7 2.9
2b 43.8 2.03 12.4 NA −2.7 NA
2c 42.6 1.08 11.7 4.4 −1.3 0.4
2d 39.9 2.54 14.1 NA 0.8 −1.5
2e 37.3 1.9 12.9 NA −2.3 1.1
2f 45.7 2.87 13.9a 4.1 −1.4 −0.4
2g 44.6 1.75 12.8a 4.6 −0.7 −0.1
2h 33.9 1.47 16.6 4.5b 0.7 1.0
3b 6.2 3.44 15.4 6.3b −2.8 NA
3f 1.0 3.28 14.3 5.1b −1.0 −1.2
Normal	Ranges	are	defined	in	brackets.
aReference	range	10-	19.8	pmol/L.	
bReference	range	3.1-	6.8	Abnormal	values	are	highlighted	in	bold.	
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F IGURE  3 Growth	chart	demonstrating	sequential	height	and	weight	SDS	in	case	3a	(pale	blue).	The	arrow	denotes	commencement	of	
levothyroxine	treatment	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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exhibited	a	growth	response	to	levothyroxine	(Figure	3)	and	3i	also	
exhibited	 improved	 growth	 after	 twelve	 months	 of	 levothyroxine	
treatment	(height	SDS	improvement	from	SDS	−1.86	to	+1.67);	how-
ever,	his	levothyroxine	dose	continues	to	be	adjusted	since	his	thy-
roid	hormone	concentrations	remain	suboptimal	 (FT4	12.4	pmol/L,	
RR	12.6-	21),	precluding	full	assessment	of	his	response.	Case	3i	had	
neonatal	 hypothermia	 and	 case	 3a	 had	 required	 dietary	 interven-
tion	for	obesity	(Figures	2	and	4;	Table	1).	However,	three	children	
(cases	3d,	3e,	and	3g)	were	apparently	clinically	euthyroid;	despite	
moderately	 subnormal	 FT4	 concentrations.	 Three	 adults	were	 ge-
netically	 ascertained	 in	 their	 6th-	8th	 decades.	 Two	 cases	 (1b,	 1c)	
with	moderate	hypothyroidism	had	previously	been	commenced	on	
levothyroxine	 aged	 56	 and	 59	years	 after	 presenting	with	 fatigue	
and	obesity,	despite	attaining	normal	height.	Case	1a	had	significant	
biochemical	 hypothyroidism	at	 diagnosis	 aged	75.5	years;	 [fT4	6.9	
(RR	12-	22	pmol/L)]	and	we	selected	 this	patient	 for	more	detailed	
biochemical	 and	 physiological	 assessment.	 Although	 obese	 (BMI	
32.1	kg/m2),	he	was	otherwise	asymptomatic,	having	attained	nor-
mal	height.	Several	biochemical	markers	of	thyroid	hormone	action	
were	normal;	cholesterol	3.9	mmol/L,	LDL-	cholesterol	2.26	mmol/L,	
CK	204	 (40-	320	mU/L),	 SHBG	36.3	 (10-	57	mmol/L),	 and	his	 IGF-	1	
concentration	(a	positively-	regulated	thyroid	hormone	target	gene)	
was	 also	 inappropriately	 in	 the	 upper	 part	 of	 the	 normal	 range	
given	his	subnormal	fT4	[IGF-	1	25.7	mmol/L,	 (RR	8.5-	30.7,	Z	score	
+1.1)].	 Cognitive	 function	 was	 not	 formally	 characterized	 but	 he	
had	 no	 overt	 neurodevelopmental	 abnormalities	 (Figures	2	 and	 4;	
Table	1,	Supporting	Information	Table	S1)	Basal	metabolic	rate	was	
normal	 (7.8	MJ/d),	 equating	 to	 101.8%	 value	 computed	 using	 the	
Schofield	predictive	equation,20	sleeping	heart	rate	was	unremark-
able	 (55	beats/min,	 RR	46-	67,	mean	55	beats/min)	 and	 clinical	 ex-
amination	 (warm	palms,	 normal	Achilles	 tendon	 reflex,	 lack	of	 dry	
skin	or	hypothyroid	facies)	did	not	reveal	any	other	features	of	hy-
pothyroidism.	Therefore,	although	other	 family	members	with	 less	
marked	biochemical	 hypothyroidism	exhibited	 some	 features	 con-
sistent	with	physiological	hypothyroidism,	surprisingly,	this	case	did	
not	have	readily	discernable	tissue		hypothyroidism	despite	markedly	
subnormal	FT4	levels.
Only	 one	 heterozygous	 female	 (case	 2c,	 aged	 42.6	years)	
	exhibited	central	hypothyroidism	[TSH	1.08	mU/L	(RR	0.3-	4.2);	FT4	
11.7	pmol/L	 (RR	 12-	22)].	 The	 majority	 of	 heterozygotes	 had	 FT4	
concentrations	in	the	lower	third	of	the	reference	range	(mean	FT4	
13.7	±	1.39	pmol/L,	mean	Z-	score	−0.5	±	0.3)	(Table	2).
3.5 | Prolactin
Prolactin	concentrations	were	usually	in	the	lower	half	of	the	refer-
ence	 range	 (hemizygotes;	mean	Z-	score	−1.5	±	1.4,	 heterozygotes;	
mean	Z	score	−1.2	±	1.2).	One	hemizygous	adult	and	three	children	
exhibited	 hypoprolactinaemia,	with	 prolactin	 concentrations	 rang-
ing	from	undetectable	(case	3a)	to	subnormal	(cases	3c,	3e,	and	1c)	
or	 low-	normal	 [case	3d,	92	mU/L	 (RR	90-	320)].	Two	heterozygous	
adults	and	one	child	were	hypoprolactinaemic;	however,	both	adults	
experienced	no	problems	with	pregnancy	although	case	2b	did	ex-
perience	difficulties	with	lactation	with	her	two	sons	(Tables	1	and	
2;	Supporting	Information	Tables	S1	and	S2).
3.6 | Gonadal axis
The	FSH:LH	ratio	was	 in	 the	upper	part	of	 the	 reference	range	 in	
the	three	male	hemizygous	adults,	mean	2.91	(RR	0.4-	3.4)	(Table	1;	
Table	S1).	Ultrasonography	 in	 case	1a	 confirmed	macro-	orchidism	
(mean	 testicular	 volume	 22.3	mL,	 Z	 score	 +2.4)	 compared	 with	
age-	matched	 reference	 data.19	 Two	 children	 (3h,	 3i)	 had	 clinically	
assessed	 testicular	 volumes	 of	 8	mL	 [(Z	 score	 −1.25),	 3h,	 aged	
14.2	years]	and	15	mL	[(Z	score	+0.25),	3i,	aged	13.9	years].	It	was	
not	possible	to	retrieve	accurate	data	regarding	pubertal	develop-
ment	in	cases	1b	and	1c.	2a	had	an	ovarian	mass	thought	to	be	a	cyst	
detected	 incidentally	 on	 ultrasound	 performed	 aged	 38	 (6	years	
prior	to	the	current	study).	2b	also	had	an	ovarian	cyst	reported	fol-
lowing	abdominal	ultrasound	for	midcycle	pain.	Histological	evalu-
ation	of	the	cysts	has	not	been	undertaken	and	neither	patient	has	
undergone	surgical	intervention.
3.7 | Growth hormone
Two	male	 cases	 had	 either	 low	 normal	 (3i)	 or	 mildly	 subnormal	
(3h)	IGF-	1	concentrations	at	diagnosis;	however,	both	were	evalu-
ated	whilst	hypothyroid	and	peripubertal	(aged	12	and	13	years);	
therefore,	 GH	 deficiency	 could	 not	 be	 definitively	 excluded	 or	
confirmed.	 Case	 3i	 showed	 improved	 growth	 on	 levothyroxine,	
but	 Case	 3h	 was	 still	 growing	 slowly	 at	 age	 14.5	years	 (height	
velocity	 4.1	cm/y,	 height	 142	cm,	 <0.4th	 centile,	 testosterone	
<0.2	nmol/L,	 pubertal	 staging	 G3,	 P1,	 A1,	 testicular	 volumes	
8	mL),	 despite	 low	 normal	 IGF-	1	 (19.7	nmol/L).	 An	 insulin	 toler-
ance	test	(ITT)	after	testosterone	priming	confirmed	growth	hor-
mone	 deficiency	 (peak	 GH	 1.8	μg/L	 at	 60	minutes).	 In	 Case	 3a,	
F IGURE  4 Distribution	of	FT4,	FT3	and	rT3	Z-	scores	in	
hemizygous	p.L773P	cases.	Cases	exhibit	subnormal	FT4,	normal	
FT3	and	low/low-	normal	rT3	concentrations.	Black	horizontal	lines	
represent	the	mean	value;	bars	denote	standard	error	of	the	mean	
(SEM).	The	population	mean	is	denoted	by	the	dashed	line	at	0
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when	thyroxine	replete,	GH	concentrations	were	insufficient	(GH	
peak	 of	 4.01	μg/L,	 baseline	 3.36	μg/L	 on	 ITT	 post-	testosterone	
priming	at	age	11.4	years),	at	which	point	testicular	volumes	were	
4	mL	bilaterally.	However,	IGF-	1	(27.3	mmol/L,	RR	10.8-	63.7)	and	
IGFBP3	 (4.07	mg/L,	RR	2.5-	6)	were	within	normal	 limits,	and	al-
though	the	test	had	been	performed	due	to	declining	growth	ve-
locity,	 this	 resolved	without	 intervention.	Cortisol	 response	was	
preserved	(peak	529	mmol/L).
Paradoxically,	 IGF-	1	 concentrations	 were	 elevated	 in	 two	 of	
nine	adult	heterozygous	 females	 [Cases	1d,	29.5	nmol/L	 (RR	11.8-	
28.6);	and	2a,	32.7	nmol/L	(RR	2.7-	28.2)]	and	were	otherwise	in	the	
mid-	normal	range	(mean	Z	score	+0.5	±	1.5),	with	the	exception	of	
Case	2d	who	had	had	renal	transplantation	following	a	diagnosis	of	
membranoproliferative	glomerulonephritis	 [IGF-	1,	11.1	nmol/L	 (RR	
8.5-	30.7)].	IGF-	1	concentrations	in	the	hemizygous	adult	males	were	
in	the	mid-	normal	 range	 (mean	Z	score	0.04	±	0.9),	but	were	more	
variable	in	the	hemizygous	male	children	(mean	Z	score	−1.46	±	0.46)	
(Tables	1	and	2;	Supporting	Information	Tables	S1	and	S2).
3.8 | TRH testing
A	TRH	 test	was	 performed	 in	 seven	males	 [1	 adult	 (Case	 1a)	 and	
six	 children	 (Cases	 3a,c,d,e,h,i)];	 five	 cases	 underwent	 prolonged	
testing.	The	TSH	peak	occurred	at	20	minutes	 in	all	cases	and	was	
normal	or	exuberant	 (mean	peak	14.4	±	8.6	mU/L	 (RR	12.9	±	3.1));	
however,	 the	maximal	 increment	 in	FT3	and	FT4	 (an	 indirect	 indi-
cator	of	TSH	bioactivity)	was	not	significantly	different	to	controls,	
although	FT3	 increment	 fell	 in	 the	 lower	half	 of	 the	normal	 range	
[22%	±	7.3	(RR	35.1	±	18.7)].	The	two	childhood	cases	exhibiting	the	
more	marked	TSH	responses	did	not	undergo	prolonged	testing	and	
were	therefore	not	included	in	this	assessment.	Peak	prolactin	was	
normal	in	four	males	with	normal	basal	prolactin	(Cases	1a,	3d,	h,	i)	
but	subnormal	in	Cases	3a	and	3e,	who	had	basal	hypoprolactinae-
mia,	although	a	fivefold	increase	in	Case	3e	confirmed	some	prolac-
tin	reserve	(Figure	5;	Supporting	Information	Table	S3).
4  | DISCUSSION
We	identified	a	novel	IGSF1	missense	mutation	in	a	three-	generation	
Irish	kindred.	This	 is	 the	 largest	reported	family	to	date,	with	endo-
crine	 evaluation	 of	 10	 hemizygous	 males	 and	 11	 heterozygous	 fe-
males.	Previously	described	IGSF1	mutations	include	four	whole-	gene	
deletions,4,11,21	multiple	 premature	 truncations	 and	missense	muta-
tions,	2	splice-	site	mutations	and	a	27-	bp	deletion	4,7,9,22-28	(Figure	1A).	
Affected	individuals	in	our	kindred	exhibit	classical	endocrine	manifes-
tations	of	IGSF1	deficiency,	and	characterization	of	the	p.L773P	muta-
tion	in	vitro	demonstrates	deficits	in	trafficking	of	the	protein	from	the	
endoplasmic	reticulum	to	the	cell	surface,	as	has	been		described	for	
previously-	reported	pathogenic	IGSF1	mutations.4,7,9
In	keeping	with	previous	 reports,	biochemical	penetrance	of	 thy-
roid	dysfunction	in	the	L773P	kindred	was	variable,	although	all	hem-
izygous	males	had	mild	or	moderate	central	hypothyroidism	according	
to	ESPE	criteria.29	Ascertainment	following	 identification	of	an	 IGSF1 
mutation	may	precipitate	diagnosis	of	moderate	central	hypothyroidism	
in	 apparently	 asymptomatic	 individuals,	whereas	 other	 subjects	with	
comparable	biochemistry	present	symptomatically,	suggesting	variable	
physiological	penetrance.4	Consistent	with	this,	Case	1a	had	the	lowest	
FT4	concentrations	(6.9	pmol/L).	However,	although	obese,	he	had	at-
tained	normal	height,	and	seemed	otherwise	physiologically	euthyroid	
when	evaluated	using	detailed	biochemical	and	physiological	indicators	
of	tissue	thyroid	status.	In	contrast,	a	subset	of	individuals	(Cases	3h,	3i,	
F IGURE  5 Peak	A,	TSH,	B,	FT3,	C,	FT4	
and	D,	sequential	prolactin	measurements	
during	a	TRH	test	in	7	(TSH,	Prolactin)	
or	5	(FT3,	FT4)	hemizygous	male	cases	
aged	2.2-	75	years.	Peak	TSH	and	prolactin	
increment	occurred	at	20	mins	in	all	
cases	and	maximal	FT3	increment,	which	
was	assessed	using	measurements	up	
to	180	min	after	administration	of	TRH,	
usually	occurred	at	150	min	(range	120-	
180	min).	Black	horizontal	lines	represent	
the	mean	value;	bars	denote	standard	
error	of	the	mean	(SEM),	and	P-	values	
were	calculated	using	a	Mann-	Whitney	U	
test.	The	Grey	box	defines	the	reference	
range	for	prolactin	peak	in	accordance	
with	published	literature;	RR	421-	
1829	mU/L,	minimum	to	maximum	32
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3a,	3c)	with	biochemically	milder	disease	exhibited	features	potentially	
consistent	with	 tissue	hypothyroidism.	Although	associated	GH	defi-
ciency	is	a	potential	confounder	in	Cases	3a	and	3h,	it	is	likely	that	hypo-
thyroidism	was	the	most	significant	contributor	to	growth	impairment	
in	3a,	given	the	improved	growth	velocity	once	levothyroxine	treatment	
alone	was	commenced.	Additionally,	3i	exhibited	a	growth	response	to	
levothyroxine	supporting	a	hypothyroid	aetiology	for	his	short	stature	
Increased	BMI	is	a	recognized	association	of	IGSF1	deficiency,	and	five	
cases	were	 obese,	 perhaps	 also	 reflecting	 tissue	 hypothyroidism9 al-
though	the	specificity	of	weight	gain	 for	 thyroid	dysfunction	 is	poor.	
Additionally,	birth	weight	SDS	was	greater	than	+2SDS	in	three	of	seven	
evaluable	hemizygotes,	which	is	also	a	recognized	feature	of	congen-
ital	hypothyroidism	as	well	as	being	reported	 in	25%	IGSF1	deficient	
males.9,30
Subnormal	 FT4	 is	 often	 associated	 with	 normal	 FT3	 concen-
trations	in	IGSF1	deficiency,	and	FT3	was	preserved	in	all	p.L773P	
males	at	diagnosis.	In	three	evaluable	cases,	rT3	was	also	subnormal	
or	low	normal,	potentially	consistent	with	preferential	deiodination	
of	FT4	to	FT3.	Although	normal	serum	FT3	concentrations	did	not	
preclude	 development	 of	 symptomatic	 hypothyroidism,	 increased	
conversion	 of	 FT4	 to	 FT3	may	modulate	 tissue	 hypothyroidism	 in	
some	 subjects.4	 Alternatively,	 a	 history	 of	 apparently	 normal	 de-
velopment	 in	 hypothyroid	 adults	 may	 reflect	 evolution	 of	 milder	
childhood	 hypothyroidism.	 Indeed,	 fluctuating	 thyroid	 hormone	
concentrations	have	previously	been	reported	in	IGSF1	deficiency;	
however,	future	studies	are	needed	to	characterize	the	natural	his-
tory	of	thyroid	dysfunction	in	this	syndrome.25
IGSF1	 is	 thought	 to	 have	 a	 role	 in	 murine	 TRH	 signalling	 since	
Igsf1	null	mice	exhibit	preserved	hypothalamic	Trh	expression	with	de-
creased	pituitary	Trhr1	mRNA	levels	and	subnormal	TSH	response	to	
exogenous	TRH.4,12	Human	studies	generally	 support	a	 similar	 func-
tion,	with	 subnormal	 (neonatal)	or	 low-	normal	 (child-	adulthood)	TSH	
response	to	TRH	in	affected	males	and	subnormal	FT4	increment	fol-
lowing	the	TSH	peak.4,9	TRH	testing	in	the	hemizygotes	reported	here	
elicited	normal	or	exuberant	TSH	responses,	and	comparable	FT4	and	
FT3	increments	to	controls,	although	FT3	fell	in	the	lower	half	of	the	
reference	range.	Impaired	post-	translational	modification	of	TSH	would	
be	an	expected	consequence	of	a	TRH	signalling	defect,	and	TSH	bio-
activity	was	markedly	subnormal	when	assessed	directly	 in	one	pre-
vious	case.11	However,	our	findings	suggest	that	TSH	bioactivity	may	
only	be	mildly	impaired	in	some	cases	of	IGSF1	deficiency,	although	this	
requires	confirmation	by	direct	quantitation	in	future	studies.
Biochemical	severity	of	hypothyroidism	did	not	predict	coexis-
tence	of	other	hormone	deficiencies;	however,	three	males	exhibited	
subnormal/borderline	basal	prolactin.	 In	keeping	with	previous	re-
ports,	hemizygous	cases	(n	=	4)	with	normal	basal	prolactin	exhibited	
a	normal	prolactin	response	to	TRH,	whereas	the	peak	was	blunted	
in	the	context	of	basal	hypoprolactinaemia	(Figure	5,	Cases	3a	and	
3e).22,23,26	The	role	of	IGSF1	in	prolactin	production	remains	unclear	
and	is	likely	to	involve	pathways	separate	from	the	TRHR,	as	TRHR	
signalling	 is	not	required	for	normal	basal	prolactin	production.2,31 
Female	hypoprolactinaemia	had	no	apparent	effect	on	pregnancy,	
although	one	individual	experienced	difficulties	with	lactation.
Although	IGSF1	expression	has	been	reported	in	murine	and	rat	
somatotrophs,	its	role	in	GH	dynamics	may	be	complex.	GH	deficiency	
occurs	 rarely	 in	 IGSF1	 deficiency;	 however,	 IGF-	1	 is	 usually	 in	 the	
upper	part	of	normal	range	in	IGSF1	deficient	adults	and	may	be	asso-
ciated	with	acromegaloid	features	consistent	with	mild	GH	excess.7,9 
In	our	kindred,	one	individual	had	GH	deficiency	and	another	had	in-
sufficient	GH	concentrations	on	stimulation	testing	with	normal	IGF-	1	
and	growth	velocity.	However,	the	potential	for	puberty	to	be	delayed	
in	the	context	of	 IGSF1	deficiency	may	complicate	 interpretation	of	
these	results.	Two	adult	heterozygotes	had	mildly	elevated	IGF-	1	con-
centrations	(Cases	1d	and	2a)	and	one	hemizygote	(Case	1a)	exhibited	
acromegaloid	 facies	with	 inappropriately	 preserved	 IGF-	1	 given	 his	
hypothyroidism.	Cortisol	production	was	not	evaluated	systematically	
in	our	kindred;	however,	transient	neonatal	hypocortisolism	has	also	
been	reported	in	IGSF1	deficiency.9	 In	this	context,	 it	 is	noteworthy	
that	3a	exhibited	neonatal	 hypoglycaemia;	 although	 this	 is	 a	 recog-
nized	phenomenon	in	babies	born	large	for	gestational	age,	we	cannot	
exclude	transient	cortisol	deficiency	in	the	neonatal	period	although	
his	cortisol	production	was	normal	when	evaluated	in	childhood.
Detection	of	CeCH	by	neonatal	screening	requires	the	inclu-
sion	of	 thyroxine	 (T4)	 in	 the	CH	screening	programme,	as	 in	 the	
Netherlands,	where	an	algorithm	including	TBG	enables	detection	
of	permanent	neonatal	central	CH.1	 In	keeping	with	current	rec-
ommendations,	our	data	support	early	initiation	of	levothyroxine	
replacement	 in	 IGSF1	deficiency,	as	sequelae	attributable	to	hy-
pothyroidism	were	evident	 in	70%	affected	males.9	Additionally,	
associated	 pubertal	 delay	 and	 GH	 deficiency	 may	 be	 amenable	
to	 treatment	 following	 endocrine	 diagnosis.	 These	 observations	
mandate	 multigenerational	 genetic	 and	 biochemical	 ascertain-
ment	 in	 all	 members	 of	 IGSF1	 deficient	 kindreds	 born	 in	 coun-
tries	such	as	Ireland	and	the	UK,	where	CH	screening	programmes	
fail	 to	detect	CeCH	neonatally,	as	well	as	 in	adults	born	prior	to	
the	 implementation	 of	 the	 screening	 in	 countries	 operating	 T4-	
based	methods.	This	may	be	a	significant	undertaking,	 spanning	
several	 healthcare	 jurisdictions.	 However,	 we	 also	 highlight	 the	
discordance	of	marked	biochemical	 central	 hypothyroidism	with	
apparent	physiological	euthyroidism	in	some	affected	individuals,	
suggesting	that	formal	studies	are	needed	to	investigate	the	ben-
efits	of	levothyroxine	therapy	in	apparently	asymptomatic	adults,	
and	to	delineate	apparent	compensatory	mechanisms	preventing	
overt	tissue	hypothyroidism	in	such	individuals.
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